Literature DB >> 14572815

Sudden upper airway obstruction in patients with hereditary angioedema.

Konrad Bork1, Nina Ressel.   

Abstract

Hereditary angioedema (HAE) is clinically characterized by recurrent and self-limiting skin, intestinal, and life-threatening laryngeal edema. This study describes the age at which laryngeal edema first occurred, the time between onset and full development, and the effectiveness of therapy and prophylaxis in 123 HAE patients. 61 (49.7%) patients experienced a total of 596 laryngeal edema episodes. The ratio of laryngeal edema episodes to skin swellings and abdominal pain attacks was approximately 1:70:54 in patients who had laryngeal edema. The mean (SD) age at the first laryngeal edema was 26.2 (15.3) years. Nearly 80% of the laryngeal edemas occurred between age 11 and 45. The mean interval between onset and maximum development of laryngeal edema was 8.3 hours. A total of 354 laryngeal edemas cleared spontaneously without treatment and 208 laryngeal edemas were successfully treated with C1 inhibitor concentrate. Despite long-term prophylactic treatment with danazol, 6 patients developed subsequent laryngeal edemas. Laryngeal edema may occur at any age, although young adults are at greatest risk. In adults, the interval between onset of symptoms and acute risk of asphyxiation is usually long enough to allow for use of appropriate emergency procedures. It is essential to instruct patients and their relatives about the first signs of laryngeal edemas and the necessary procedures to follow.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14572815     DOI: 10.1016/j.transci.2003.08.007

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  14 in total

1.  Preventing Hereditary Angioedema Attacks in Children Using Cinryze®: Interim Efficacy and Safety Phase 3 Findings.

Authors:  Emel Aygören-Pürsün; Daniel Soteres; Dumitru Moldovan; Jim Christensen; Arthur Van Leerberghe; James Hao; Jennifer Schranz; Kraig W Jacobson; Inmaculada Martinez-Saguer
Journal:  Int Arch Allergy Immunol       Date:  2017-06-30       Impact factor: 2.749

Review 2.  C1 inhibitor: molecular and clinical aspects.

Authors:  Marco Cicardi; Lorenza Zingale; Andrea Zanichelli; Emanuela Pappalardo; Benedetta Cicardi
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

Review 3.  Sudden death by laryngeal polyp: a case report and review of the literature.

Authors:  Jeff Tanguay; Michael Pollanen
Journal:  Forensic Sci Med Pathol       Date:  2008-09-25       Impact factor: 2.007

Review 4.  Management of acute attacks of hereditary angioedema: potential role of icatibant.

Authors:  Hilary J Longhurst
Journal:  Vasc Health Risk Manag       Date:  2010-09-07

5.  Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema.

Authors:  Timothy J Craig; Richard L Wasserman; Robyn J Levy; Againdra K Bewtra; Lynda Schneider; Flint Packer; William H Yang; Heinz-Otto Keinecke; Peter C Kiessling
Journal:  J Clin Immunol       Date:  2010-07-16       Impact factor: 8.317

6.  2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema.

Authors:  Tom Bowen; Marco Cicardi; Henriette Farkas; Konrad Bork; Hilary J Longhurst; Bruce Zuraw; Emel Aygoeren-Pürsün; Timothy Craig; Karen Binkley; Jacques Hebert; Bruce Ritchie; Laurence Bouillet; Stephen Betschel; Della Cogar; John Dean; Ramachand Devaraj; Azza Hamed; Palinder Kamra; Paul K Keith; Gina Lacuesta; Eric Leith; Harriet Lyons; Sean Mace; Barbara Mako; Doris Neurath; Man-Chiu Poon; Georges-Etienne Rivard; Robert Schellenberg; Dereth Rowan; Anne Rowe; Donald Stark; Smeeksha Sur; Ellie Tsai; Richard Warrington; Susan Waserman; Rohan Ameratunga; Jonathan Bernstein; Janne Björkander; Kristylea Brosz; John Brosz; Anette Bygum; Teresa Caballero; Mike Frank; George Fust; George Harmat; Amin Kanani; Wolfhart Kreuz; Marcel Levi; Henry Li; Inmaculada Martinez-Saguer; Dumitru Moldovan; Istvan Nagy; Erik W Nielsen; Patrik Nordenfelt; Avner Reshef; Eva Rusicke; Sarah Smith-Foltz; Peter Späth; Lilian Varga; Zhi Yu Xiang
Journal:  Allergy Asthma Clin Immunol       Date:  2010-07-28       Impact factor: 3.406

Review 7.  Managing the female patient with hereditary angioedema.

Authors:  Aleena Banerji; Marc Riedl
Journal:  Womens Health (Lond)       Date:  2016-03-15

Review 8.  Current and emerging management options for hereditary angioedema in the US.

Authors:  Tolly G Epstein; Jonathan A Bernstein
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  The hereditary angioedema burden of illness study in Europe (HAE-BOIS-Europe): background and methodology.

Authors:  Anette Bygum; Emel Aygören-Pürsün; Teresa Caballero; Kathleen Beusterien; Shadi Gholizadeh; Patience Musingarimi; Suzanne Wait; Henrik Boysen
Journal:  BMC Dermatol       Date:  2012-04-26

10.  Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency.

Authors:  Henriette Farkas; Lilian Varga
Journal:  Clin Cosmet Investig Dermatol       Date:  2011-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.